Profound Medical Corp. (PROF) Income Statement
PROF 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPROF revenue and net income
Where PROF's revenue goes
2025Each bar shows an amount and its share of revenue. PROF kept −264.4% of revenue as net income.
PROF profit margins
PROF growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +61.1% | +34.8% | +17.5% | — |
| Gross profit | +73.0% | +56.6% | +27.3% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PROF quarterly EPS vs estimates
Profound Medical beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.19).
PROF income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.4M | $10.2M | $7.2M | $6.7M | $6.9M | $7.3M | $4.2M | $1.9M | $4.9M | $0 |
| Cost of revenue | $4.8M | $3.5M | $2.8M | $3.7M | $3.9M | $3.8M | $1.8M | $1.3M | $3.0M | $188,385 |
| Gross profit | $11.6M | $6.7M | $4.4M | $3.0M | $3.0M | $3.5M | $2.4M | $604,815 | $1.9M | −$188,385 |
| Research & development | $21.0M | $16.2M | $14.4M | $14.7M | $15.3M | $9.9M | $9.4M | $7.5M | $7.7M | $7.4M |
| Sales, general & admin | $32.1M | $23.1M | $18.6M | $17.9M | $18.0M | $12.4M | $7.9M | $7.9M | $7.8M | $5.2M |
| Total operating expenses | $53.6M | $38.2M | $33.0M | $35.1M | $33.2M | $22.3M | $17.3M | $15.4M | $19.1M | $16.2M |
| Operating income | −$42.0M | −$31.5M | −$28.6M | −$32.1M | −$30.3M | −$18.9M | −$14.9M | −$14.8M | −$17.2M | −$16.2M |
| Interest income | — | — | $1.6M | $803,000 | $205,000 | $692,000 | $481,309 | $483,788 | $127,732 | $157,598 |
| Interest expense | — | — | $770,000 | $167,105 | $66,410 | $543,000 | $1.0M | $755,374 | $1.1M | $615,868 |
| Income before taxes | −$43.1M | −$26.5M | −$28.7M | −$28.4M | −$30.6M | −$21.6M | −$15.1M | −$15.1M | −$18.7M | −$16.3M |
| Income taxes | $256,411 | −$1,903 | −$128,000 | $287,000 | $105,000 | $45,000 | $147,000 | $169,441 | $74,123 | $14,054 |
| Net income | −$43.3M | −$26.5M | −$28.6M | −$28.7M | −$30.7M | −$21.6M | −$15.2M | −$15.2M | −$19.1M | −$12.1M |
| EBITDA | −$41.4M | −$25.5M | −$27.0M | −$26.6M | −$28.6M | −$19.5M | −$12.5M | −$19.0M | −$16.2M | −$15.6M |
| EPS (diluted) | −$1.41 | −$1.12 | −$1.35 | −$1.38 | −$1.50 | −$1.35 | −$1.35 | −$1.73 | −$1.89 | −$1.62 |
| Gross margin | 70.8% | 65.9% | 60.9% | 45.2% | 43.0% | 47.6% | 57.3% | 31.7% | 38.2% | — |
| Operating margin | −256.3% | −309.6% | −397.5% | −480.9% | −440.7% | −258.3% | −357.1% | −776.0% | −349.7% | — |
| Net margin | −264.4% | −260.4% | −396.8% | −429.1% | −446.7% | −296.0% | −364.7% | −797.9% | −389.4% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $5.3M | $6.0M | $5.3M | $2.2M | $2.6M | $4.1M | $2.8M | $2.2M | $1.4M | $2.7M | $1.7M |
| Cost of revenue | $536,000 | $1.5M | $2.0M | $1.4M | $593,000 | $768,000 | $1.2M | $1.0M | $795,000 | $573,000 | $1.4M | $668,000 |
| Gross profit | $1.9M | $3.8M | $4.0M | $3.9M | $1.6M | $1.9M | $2.9M | $1.8M | $1.4M | $866,000 | $1.3M | $1.1M |
| Research & development | $5.7M | $5.2M | $4.3M | $5.4M | $6.1M | $4.8M | $4.6M | $5.6M | $4.2M | $3.9M | $5.3M | $3.4M |
| Sales, general & admin | $7.4M | $6.6M | $7.1M | $7.4M | $9.3M | $8.2M | $11.8M | $6.6M | $2.1M | $4.8M | $16.9M | $4.2M |
| Total operating expenses | $13.0M | $11.7M | $11.4M | $12.8M | $15.4M | $13.0M | $11.0M | $12.2M | −$6.4M | $8.7M | $65.6M | $7.6M |
| Operating income | −$11.1M | −$7.9M | −$7.4M | −$8.9M | −$13.8M | −$11.2M | −$8.1M | −$10.4M | $7.8M | −$7.9M | −$64.2M | −$6.6M |
| Interest income | — | — | — | — | — | — | — | — | — | — | $1.4M | $1.0M |
| Interest expense | — | — | — | — | $147,246 | — | $419,283 | $199,000 | $147,246 | $471,037 | $343,231 | $195,411 |
| Income before taxes | −$9.5M | −$6.9M | −$8.1M | −$7.9M | −$15.6M | −$10.7M | −$5.6M | −$9.2M | −$6.9M | −$6.5M | −$11.8M | −$5.5M |
| Income taxes | $55,000 | $24,653 | $26,000 | $121,000 | $64,000 | $41,000 | −$231,283 | $177,000 | $20,000 | $40,000 | −$303,418 | $18,000 |
| Net income | −$9.5M | −$7.0M | −$8.2M | −$8.0M | −$15.7M | −$10.7M | −$5.3M | −$9.4M | −$6.9M | −$6.6M | −$11.5M | −$5.6M |
| EBITDA | −$9.3M | −$7.8M | −$7.3M | −$8.8M | −$13.7M | −$11.0M | −$8.0M | −$10.2M | −$7.5M | −$7.6M | −$11.4M | −$19.4M |
| EPS (diluted) | $0.26 | −$0.19 | −$0.27 | −$0.26 | −$0.52 | −$0.36 | −$0.20 | −$0.38 | −$0.28 | −$0.26 | −$0.42 | −$0.26 |
| Gross margin | 78.4% | 71.8% | 66.8% | 74.3% | 73.2% | 70.7% | 70.9% | 63.1% | 64.4% | 60.2% | 49.2% | 61.3% |
| Operating margin | −445.7% | −150.3% | −123.3% | −168.5% | −624.4% | −426.0% | −199.8% | −369.0% | 350.8% | −547.4% | −2,413.4% | −379.6% |
| Net margin | −384.2% | −132.2% | −136.8% | −150.8% | −709.9% | −409.2% | −131.4% | −330.7% | −309.9% | −457.6% | −431.2% | −322.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PROF's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PROF financial results
In fiscal year 2025 (ended December 31, 2025), Profound Medical reported revenue of $16.4 million, up 61.1% from the year before. It had a net loss of $43.3 million, a net profit margin of −264.4%. Diluted earnings per share came to −$1.41. Over five years revenue grew at an average rate of 17.5% a year.
See the PROF stock overview for the latest quote and news, or the PROF chart for price history and technical indicators.
PROF income statement FAQ
What is Profound Medical's annual revenue?
Profound Medical reported total revenue of $16.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 61.1% from $10.2 million the previous year.
Is Profound Medical profitable?
No. Profound Medical reported a net loss of $43.3 million in fiscal 2025, a net profit margin of −264.4%; its operating margin was −256.3%.
What is Profound Medical's gross margin?
Profound Medical's gross margin was 70.8% in fiscal 2025: for every $100 of revenue, Profound Medical kept $71 after the direct cost of its products and services.
How much does Profound Medical spend on research and development?
Profound Medical spent $21.0 million on research and development in fiscal 2025, 127.9% of revenue.
How fast is Profound Medical growing?
Revenue grew 17.5% a year on average over the last five fiscal years, from $7.3 million to $16.4 million.
What are Profound Medical's earnings per share?
Profound Medical earned $-1.41 per diluted share in fiscal 2025, compared with $-1.12 a year earlier.
When will Profound Medical report its next earnings?
Profound Medical is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Profound Medical's fiscal year end?
Profound Medical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.